Connect your AI

LBRX LBRX Operating lease liabilities

Operating lease liabilities at other companies

MapLight Therapeutics, Inc. MPLT

——

Zevra Therapeutics, Inc.ZVRA

——

Septerna, Inc.SEPN

——

Xenon PharmaceuticalsXENE

——

Praxis Precision Medicines, Inc.PRAX

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

Net income-$19.1M-259%

EPS (diluted)-$0.67+95.5%

Balance sheet

Cash & equivalents$320.7M—

Total debt$3.5M—

Total equity$378.7M+481%

Total assets$393.5M—

Cash flow

Operating cash flow-$23.3M-187%

CapEx$32.0K+52.4%

Free cash flow-$23.3M-186%

Valuation

Market cap$874.06M+163%

Enterprise value$556.86M—

Returns & leverage

Return on equity-27.9%—

Debt / equity0×—

Current ratio35.7×—

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is LBRX's operating lease liabilities?: LBRX (LBRX) reported operating lease liabilities of -$99K in Q1 2026.
How has LBRX's operating lease liabilities changed year-over-year?: LBRX's operating lease liabilities decreased by 5050.0% year-over-year, from $2K to -$99K.